SAR125844 |
| Katalog-Nr.GC33189 |
SAR125844 ist ein potenter, hochselektiver, reversibler und ATP-kompetitiver MET-Rezeptor-Tyrosinkinase (RTK)-Inhibitor mit einem IC50 von 4,2 nM. Zeigt die Hemmung der MET-Autophosphorylierung in zellbasierten Assays.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1116743-46-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor for intravenous administration, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays[1].
[1]. Egile C, et al. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *